Fate Therapeutics, Inc. Common Stock (NASDAQ: FATE) last traded at $2.00, down 6.10% on the session. The quote above updates while this page is open; the figures below are drawn from Fate Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Fate Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker FATE. Its market capitalisation is $239.64 million.
Valuation measures for Fate Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $239.64M |
|---|---|
| Enterprise value | $313.88M |
| Price / sales | 36.92 |
| Price / book | 1.56 |
| Beta | 2.06 |
Trailing-twelve-month figures tagged in Fate Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $6.49M |
|---|---|
| Net income (TTM) | -$126.00M |
| EPS (TTM) | -$1.05 |
| Operating margin | -2058.08% |
| Return on equity | -82.12% |
| Cash | $32.43M |
Range and volume for FATE over the past 52 weeks.
| 52-week high | $3.23 |
|---|---|
| 52-week low | $0.950 |
| Volume | 952.5K |
| Average volume | 1.67M |
| Previous close | $2.13 |
Invest a chosen dollar amount in Fate Therapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell FATE.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.